What is Adamax?

Adamax is a synthetic peptide that is an analogue of Semax (a derivative of the ACTH₄₋₁₀ fragment with the sequence Met–Glu–His–Phe–Pro–Gly–Pro), most commonly described as Ac–Met–Glu–His–Phe–Pro–Gly–Pro–Ala–Gly–NH₂ or a variant with an additional adamantyl modification. Terminal modifications (N-terminal acetylation and alterations at the C-terminus) increase resistance to enzymatic degradation and influence the physicochemical properties of the molecule.

This compound was developed as a research model as part of work on stable analogues of short ACTH-derived peptides. Due to the introduced structural modifications and specific lipophilicity, Adamax constitutes a useful tool for research into peptide signalling in experimental systems.

In preclinical research, it is used to analyse mechanisms related to the modulation of neurotrophic factor expression (including BDNF and NGF), the activation of pathways dependent on TrkB receptors and melanocortin receptors (MC3/MC4), as well as to evaluate the general organisation of cellular processes in in vitro and in vivo models. Attention has been drawn to its interactions with signalling pathways and its indirect influence on processes induced by oxidative stress under experimental conditions.

Due to its precisely defined chemical structure and the reproducibility of observed biological effects in preclinical models, Adamax is used as a research tool in molecular biology, cellular neurobiology and experimental pharmacology. In scientific literature, it is sometimes utilised as a reference peptide for the evaluation of neurotrophic signalling processes and for the validation of analytical methods used in the study of short bioactive peptides.

Disclaimer

Products in this category are not medicines, foodstuffs or dietary supplements. The products are classified as chemical reagents/reference materials authorised for marketing within the European Union and may be used exclusively for laboratory scientific research.